Crohn’s disease (CD) and ulcerative colitis (UC) are chronic relapsing/remitting inflammatory diseases of the gastrointestinal tract that typically manifest symptoms including diarrhea, abdominal pain, and weight loss. The TreatmentTrends: Crohn’s Disease and Ulcerative Colitis 2015 (US) report provides valuable insights into the market dynamics and competitive landscape of these conditions through comprehensive primary market research with U.S. gastroenterologists who treat patients with these diseases. The report focuses on current use of biological products prescribed for CD/UC, their patient share, strengths and weaknesses of key brands, barriers to broader usage of biological agents, and gastroenterologists’ awareness of and interest in key emerging therapies.
Questions Answered in This Report:
- The established TNF-alpha (?) inhibitors, Janssen Biotech’s infliximab (Remicade) and AbbVie’s adalimumab (Humira), have been the dominant biologics in both the CD and UC markets for several years. How have the launches of newer biologics affected both these agents’ dominance in the CD and UC markets? What are the reasons driving physicians’ preference for prescribing certain biologics ahead of others? In which circumstances do physicians prefer newer therapies to more-established agents?
- Despite that physicians report increasingly more-aggressive use of biologics for CD and UC, the patient share is moderate. What are the reasons why gastroenterologists do not prescribe more biologics in CD and UC? What challenges do clinicians encounter that limit greater uptake of biologics? What are the primary reasons for UC and CD patients discontinuing treatment with specific biological therapies?
- Experts frequently report that unmet need exists in the UC and CD market for new treatments, especially for patients with moderate to severe disease. What are the top unmet needs in the UC and CD markets? What late-stage therapies in development are gastroenterologists most aware of, and which ones are they most interested in?
Markets covered: United States.
Primary research: Online survey of 99 U.S. gastroenterologists treating a minimum of 30 adult patients with CD, 30 adult patients with UC, and at least 10 CD and 10 UC patients with a biological agent.
Emerging therapies: Phase III: 5 drugs.